BRWA
ATNM icon

B. Riley Wealth Advisors’s Actinium Pharmaceuticals ATNM Stock Holding History

B. Riley Wealth Advisors’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-13,006
Closed -$96.2K – 1272
2024
Q2 		$96.2K Sell
13,006
-1,544
-11% -$12.7K ﹤0.01% 1313
2024
Q1 		$86.1K Hold
14,550
– – ﹤0.01% 1369
2023
Q4 		$73.9K Hold
14,550
– – ﹤0.01% 1339
2023
Q3 		$86.1K Buy
14,550
+1,600
+12% +$10.6K ﹤0.01% 1369
2023
Q2 		$96.1K Hold
12,950
– – ﹤0.01% 1439
2023
Q1 		$122K Buy
+12,950
New +$137K ﹤0.01% 1359

Other funds holding ATNM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Los Angeles Capital Management
Los Angeles Capital Management Los Angeles, California $25.4B AUM 38.46% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

B. Riley Wealth Advisors's ATNM Position: Q3 2024 in Review

B. Riley Wealth Advisors sold out of Actinium Pharmaceuticals (ATNM) in Q3 2024, closing a stake of 13,006 shares — an estimated $96.2K sold.

B. Riley Wealth Advisors first reported a position in ATNM in Q1 2023 and held it in 6 quarters. The position peaked at $122K in Q1 2023. 72 funds tracked by Wall St. Rank hold ATNM as of Q3 2024.

  • B. Riley Wealth Advisors reported no remaining Actinium Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • B. Riley Wealth Advisors sold 13,006 Actinium Pharmaceuticals shares in Q3 2024, an estimated $96.2K.
  • B. Riley Wealth Advisors first reported a position in Actinium Pharmaceuticals in Q1 2023 and held it in 6 quarters.
  • B. Riley Wealth Advisors's Actinium Pharmaceuticals position peaked at $122K in Q1 2023.
  • 72 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q3 2024.

Based on B. Riley Wealth Advisors's 13F filing for Q3 2024, filed 13 Dec 2024.